Skip to main content

Volume 13 Supplement 1

Bronchiectasis: still an orphan disease?

Proceedings

Publication of this supplement was funded by Novamedia and Italian Respiratory Society (IRS). The articles have undergone the journal's standard peer review process for supplements. SA is an associate editor of Multidisciplinary Respiratory Medicine, also a speaker or on advisory boards on bronchiectasis, non-tuberculous mycobacteria and low respiratory tract infection for the following: Bayer, Insmed, Cheiesi, Menarini, Mundipharma, GlaxoSmithKline, AstraZeneca, Grifols, Guidotti, Malesci, Zambon, Quinsair, Actavis, Novartis, BI, Raptor, Horizon Pharma. JC has recevied research grants from Aradigm Corporation, Bayer Healthcare, Grifols, AstraZeneca, GlaxoSmithKline and Boehringer-Ingelheim. JC also received consulting fees from Aradigm Corporation, Bayer Healthcare, Grifols, GlaxoSmithKline, Boehringer Ingelheim, Chiesi, Pfizer and Napp.

Milan, Italy06-08 July 2017

Conference website

Edited by James Chalmers and Stefano Aliberti

New Content Item

  2. The contemporary diagnosis of bronchiectasis requires CT scanning to describe specific structural lung changes. Scoring systems have been designed and validated in some specific causes of bronchiectasis to all...

    Authors: Philip Robinson and Lucy Morgan

    Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):24

    Content type: Short Report

    Published on:

  3. Determining the effects of antimicrobial therapies on airway microbiology at a population-level is essential. Such analysis allows, for example, surveillance of antibiotic-induced changes in pathogen prevalenc...

    Authors: Steven L. Taylor, Lex E. X. Leong, Fredrick M. Mobegi, Jocelyn M. Choo, Lucy D. Burr, Steve Wesselingh and Geraint B. Rogers

    Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):30

    Content type: Short Report

    Published on:

  4. A substantial increase in pulmonary and extra-pulmonary diseases due to non-tuberculous mycobacteria (NTM) has been documented worldwide, especially among subjects suffering from chronic respiratory diseases a...

    Authors: Stefano Aliberti, Luigi Ruffo Codecasa, Andrea Gori, Giovanni Sotgiu, Maura Spotti, Antonio Di Biagio, Andrea Calcagno, Stefano Nardini, Baroukh Maurice Assael, Enrico Tortoli, Giorgio Besozzi, Maurizio Ferrarese, Alberto Matteelli, Enrico Girardi, Saverio De Lorenzo, Manuela Seia…

    Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):33

    Content type: Original Research Article

    Published on:

  5. Bronchiectasis is the final result of different processes and most of the guidelines advocate for a careful evaluation of those etiologies which might be treated or might change patients’ management, including...

    Authors: Andrea Gramegna, Stefano Aliberti, Manuela Seia, Luigi Porcaro, Vera Bianchi, Carlo Castellani, Paola Melotti, Claudio Sorio, Enza Consalvo, Elisa Franceschi, Francesco Amati, Martina Contarini, Michele Gaffuri, Luca Roncoroni, Barbara Vigone, Angela Bellofiore…

    Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):29

    Content type: Review

    Published on:

  6. Bronchiectasis represents the final pathway of several infectious, genetic, immunologic or allergic disorders. Accurate and prompt identification of the underlying cause is a key recommendation of several inte...

    Authors: Martina Contarini, Amelia Shoemark, Jessica Rademacher, Simon Finch, Andrea Gramegna, Michele Gaffuri, Luca Roncoroni, Manuela Seia, Felix C. Ringshausen, Tobias Welte, Francesco Blasi, Stefano Aliberti and James D. Chalmers

    Citation: Multidisciplinary Respiratory Medicine 2018 13(Suppl 1):26

    Content type: Review

    Published on:

Multidisciplinary Respiratory Medicine

ISSN: 2049-6958

Contact us

\